129 related articles for article (PubMed ID: 21246897)
21. Rivastigmine for the treatment of dementia in patients with progressive supranuclear palsy: Clinical observations as a basis for power calculations and safety analysis.
Liepelt I; Gaenslen A; Godau J; Di Santo A; Schweitzer KJ; Gasser T; Berg D
Alzheimers Dement; 2010 Jan; 6(1):70-4. PubMed ID: 20129321
[TBL] [Abstract][Full Text] [Related]
22. [Rivastigmine solution prescribing habits in patients with Alzheimer-type dementia in Spain (RIVASOL study)].
González-Gutiérrez JL; Gobartt AL;
Rev Neurol; 2007 Jun 16-30; 44(12):705-10. PubMed ID: 17583861
[TBL] [Abstract][Full Text] [Related]
23. A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease.
Karaman Y; Erdoğan F; Köseoğlu E; Turan T; Ersoy AO
Dement Geriatr Cogn Disord; 2005; 19(1):51-6. PubMed ID: 15383747
[TBL] [Abstract][Full Text] [Related]
24. Rivastigmine for dementia associated with Parkinson's disease.
Emre M; Aarsland D; Albanese A; Byrne EJ; Deuschl G; De Deyn PP; Durif F; Kulisevsky J; van Laar T; Lees A; Poewe W; Robillard A; Rosa MM; Wolters E; Quarg P; Tekin S; Lane R
N Engl J Med; 2004 Dec; 351(24):2509-18. PubMed ID: 15590953
[TBL] [Abstract][Full Text] [Related]
25. Rivastigmine: new indication. Dementia and Parkinson's disease: no thank you!
Prescrire Int; 2007 Apr; 16(88):66. PubMed ID: 17458048
[TBL] [Abstract][Full Text] [Related]
26. [Rivastigmine as treatment for patients with mild to moderately severe Alzheimer disease under normal clinical practice conditions. The ENTERPRISE study].
Cruz Jentoft AJ; Hernández B
Neurologia; 2014; 29(1):1-10. PubMed ID: 23582372
[TBL] [Abstract][Full Text] [Related]
27. Effect of rivastigmine in the treatment of behavioral disturbances associated with dementia: review of neuropsychiatric impairment in Alzheimer's disease.
Grossberg GT
Curr Med Res Opin; 2005 Oct; 21(10):1631-9. PubMed ID: 16238903
[TBL] [Abstract][Full Text] [Related]
28. [Hallucinations associated to treatment with rivastigmine in two patients with diffuse Lewy body disease].
Alonso-Navarro H; Jiménez-Jiménez FJ
Rev Neurol; 2007 May 1-15; 44(9):575-6. PubMed ID: 17492618
[No Abstract] [Full Text] [Related]
29. Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment.
Dantoine T; Auriacombe S; Sarazin M; Becker H; Pere JJ; Bourdeix I
Int J Clin Pract; 2006 Jan; 60(1):110-8. PubMed ID: 16409439
[TBL] [Abstract][Full Text] [Related]
30. Cognitive function in early clinical phase huntington disease after rivastigmine treatment.
Sešok S; Bolle N; Kobal J; Bucik V; Vodušek DB
Psychiatr Danub; 2014 Sep; 26(3):239-48. PubMed ID: 25191771
[TBL] [Abstract][Full Text] [Related]
31. [Alzheimer disease. Pseudo-irreversible AChE inhibition with rivastigmine].
Med Monatsschr Pharm; 1998 Aug; 21(8):248-9. PubMed ID: 9758554
[No Abstract] [Full Text] [Related]
32. Rivastigmine (Exelon) for Alzheimer's disease.
Med Lett Drugs Ther; 2000 Oct; 42(1089):93-4. PubMed ID: 11015159
[No Abstract] [Full Text] [Related]
33. Realizing early treatment benefits in dementia.
Gauthier SG
Eur J Neurol; 2005 Oct; 12 Suppl 3():1-2. PubMed ID: 16144530
[No Abstract] [Full Text] [Related]
34. From high doses of oral rivastigmine to transdermal rivastigmine patches: user experience and satisfaction among caregivers of patients with mild to moderate Alzheimer disease.
Reñé R; Ricart J; Hernández B;
Neurologia; 2014 Mar; 29(2):86-93. PubMed ID: 23684446
[TBL] [Abstract][Full Text] [Related]
35. Rivastigmine for subcortical vascular dementia.
Román GC
Expert Rev Neurother; 2005 May; 5(3):309-13. PubMed ID: 15938663
[TBL] [Abstract][Full Text] [Related]
36. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study.
Poewe W; Wolters E; Emre M; Onofrj M; Hsu C; Tekin S; Lane R;
Mov Disord; 2006 Apr; 21(4):456-61. PubMed ID: 16229010
[TBL] [Abstract][Full Text] [Related]
37. Protective effect of rivastigmine against 3-nitropropionic acid-induced Huntington's disease like symptoms: possible behavioural, biochemical and cellular alterations.
Kumar P; Kumar A
Eur J Pharmacol; 2009 Aug; 615(1-3):91-101. PubMed ID: 19445928
[TBL] [Abstract][Full Text] [Related]
38. Rivastigmine in Parkinson's disease dementia.
Chitnis S; Rao J
Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):941-55. PubMed ID: 19619073
[TBL] [Abstract][Full Text] [Related]
39. [Rivastigmine].
Monji A
Nihon Rinsho; 2011 Dec; 69 Suppl 10 Pt 2():36-40. PubMed ID: 22755152
[No Abstract] [Full Text] [Related]
40. [Rivastigmine for Alzheimer disease; evaluation of preliminary results and of structured assessment of efficacy].
Schölzel-Dorenbos CJ
Ned Tijdschr Geneeskd; 2002 Mar; 146(10):494. PubMed ID: 11913117
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
